The Epidemiological Characteristics of Mycoplasma Pneumoniae Infection and Coinfection among Children in Central China from 2018 to 2023

doi:10.21203/rs.3.rs-4617945/v1

Download PDF

Research Article

The Epidemiological Characteristics of Mycoplasma Pneumoniae Infection and Coinfection among Children in Central China from 2018 to 2023

https://doi.org/10.21203/rs.3.rs-4617945/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background

Mycoplasm pneumomiae(M. pneumoniae, MP) is a common cause of reapiratory infections in humans, particularly among children and adolescents. This study investigates the epidemiological characteristics of MP infection among children and its relationship with coinfections to provide guidance for local MP prevention strategies.

Methods

After data screening based on the inclusion and exclusion criteria, a total of 163,058 pediatric patients with Acute Respiratory Tract Infection (ARTI) were enrolled in the study, ranging from January 1, 2018, to December 31, 2023.

Results

From 2018 to 2023, a total of 49,936 cases tested positive for MP, resulting in an overall positive rate of 30.62%. During this period, the annual positive rates were as follows: 45.92%, 32.23%, 22.84%, 16.22%, 16.26%, and 42.93%, respectively. The highest positive rate was observed in autumn (35.13%, P < 0.001). School-aged children exhibited the highest positive rate (40.09%), while infants had the lowest (25.32%, P < 0.001). Furthermore, the positive rate among girls (34.15%) was higher than that among boys (28.01%, P < 0.001). Among patients with MP infection, 14.27% were found to have coinfection with other pathogens, with viral infections accounting for 71.36% and bacterial infections for 28.64%. Notably, infants were more prone to coinfection with multiple pathogens (48.98%, P < 0.001).

Conclusions

MP infection is prevalent in children, with notable seasonal and age-dependent variations in positive rates. Coinfection with other pathogens is common, particularly in infants.

Children

Mycoplasma pneumoniae

Acute Respiratory Tract Infection

Epidemiology

Coinfection

Mycoplasma pneumoniae, also known as M. pneumoniae or MP, is a member of the Mollicutes class and is recognized as the smallest self-sufficient pathogenic microorganism capable of independent survival. It is primarily transmitted through respiratory droplets and is commonly found in densely populated areas, including households, schools, and military bases, with an incubation period ranging from 1 to 3 weeks [1-3]. MP remains active throughout the year and can impact individuals across all age groups, with school-aged children and adolescents being particularly vulnerable. Moreover, it demonstrates a cyclical epidemic pattern, marked by significant outbreaks recurring every 3-7 years and enduring for approximately 1-2 years each time. Certain studies propose that this cyclic trend might stem from subtype alterations or temporary acquisition of herd immunity [4, 5]. Its prolonged latency period and persistence in the respiratory tract after infection may contribute to the prolonged duration of MP outbreaks [1].

MP is one of the most frequent pathogens responsible for upper and lower respiratory tract infections. Research suggests that MP is accountable for 20%-40% of community acquired pneumonia cases, with this percentage increasing during outbreaks, making it a common cause of childhood mortality [1, 5-7]. Research on community-acquired pneumonia in Asian countries found that the rate of positivity for MP was around 11% [8].Monitoring of MP infections in 11 European countries from 2011 to 2016 reported an overall positive rate of 16%, with Norway contributing the highest rate at 26% [9]. A prospective study conducted in 12 centers across seven cities in China found MP to be a dominant pathogen, with a positive rate as high as 20.7% [10].A study in Wuhan from 2020 to 2022 found that 36.6% of children with community acquired pneumonia were confirmed to be MP positive [11].Most studies suggest that illnesses caused by MP infections are self-limiting and often present with mild clinical symptoms such as fever, cough, sore throat, and headache. Rhinitis and wheezing are common in children under 5 years old, with atypical findings on chest imaging [7, 12].Apart from causing common conditions like tracheobronchitis and atypical pneumonia, a nationwide cohort study in Taiwan provided a detailed description of the relationship between MP and asthma, suggesting that toxins produced by MP infection may be causative factors or exacerbate asthma [13].Additionally, MP can manifest extrapulmonary symptoms, including involvement of the central nervous system, skin manifestations, hemolytic anemia, cardiovascular complications, renal dysfunction, gastrointestinal discomfort, and musculoskeletal issues, sometimes leading to fatal consequences. These extrapulmonary manifestations are often associated with the direct impact of MP infection or immune-mediated inflammatory responses [14, 15].

Coinfection of MP with other respiratory pathogens is also quite common, especially in children, and may lead to more severe clinical symptoms. A study on coinfection with Streptococcus pneumoniae in Mycoplasma pneumoniae pneumonia found that patients with combined infections had longer duration of fever and were more likely to develop lobar consolidation and parapneumonic effusion [16].However, the correlation between them still requires further investigation. Other studies suggest that coinfection of MP with respiratory viruses may be associated with refractory Mycoplasma pneumoniae pneumonia, characterized by severe pneumonia and poor response to treatment [17].Therefore, coinfection with other pathogens may significantly influence clinical outcomes. Despite numerous epidemiological studies on MP in the region, data on recent trends in MP outbreaks and associated coinfections analysis are lacking. Thus, this study aims to report on the changing trends, epidemiological characteristics, and coinfection analysis of MP infections from 2018 to 2023, providing evidence for clinical diagnosis and treatment and the development of corresponding prevention and control strategies.

2.1 Sample Source

The clinical data for this study were sourced from the Laboratory Information Systems of Renmin Hospital of Wuhan University. A total of 163,058 specimens were collected from children aged 0-14 with ARTI treated at Renmin Hospital of Wuhan University from January 1, 2018, to December 31, 2023. The enrolled children were grouped based on season (spring: March to May, summer: June to August, autumn: September to November, winter: December to February of the following year), age (infants: 0≤Age≤3 years old, preschool age: 3<Age≤7 years old, school age: 7<Age≤14 years old), and gender.

Inclusion Criteria:(1) Children exhibiting any of the following clinical symptoms of ARTI : new onset fever,cough,sore throat,dyspnea,and abnormal breath sounds.(2) Patients aged ≤14 years old. Exclusion Criteria:(1) Individuals not meeting the clinical presentation criteria for ARTI as described above. (2) Patients >14 years old. (3) Cases with incomplete information.

2.2 Laboratory Diagnosis

All enrolled children had specimens collected promptly (either at the time of outpatient visit or within 3 days of hospitalization for inpatients). The specimen types included whole blood, serum, nasal swabs, nasopharyngeal swabs, sputum, and bronchoalveolar lavage fluid. Whole blood specimens were used for MP specific IgM antibody titer determination, while the remaining specimens were used for MP nucleic acid detection. In addition to MP, eight common viruses and other atypical pathogens (Chlamydia pneumoniae, Legionella pneumophila, and Coxiella burnetii) were tested. Specific IgM antibody detection was performed using the following kits: IIFT: Respiratory Tract Profile (EUROIMMUN Medizinische Labordiagnostika AG, Seekamp, Lubeck, Germany) and Mycoplasma pneumoniae IgM Antibody Test Kit (Colloidal Gold Method) (Beijing Beier Bioengineering Co., Daxing, Beijing, China). Nucleic acid detection was conducted using a 13-Respiratory Pathogen Multiplex Detection kit (HEALTH BioMed Co., Ltd., Ningbo, Zhejiang, China). Additionally, specimens obtained from the lower respiratory tract underwent bacterial testing for 10 respiratory bacteria, using the Respiratory Pathogen Nucleic Acid Detection Test Kit (CapitalBio Technology (Chengdu) Co., Ltd., Wenjiang, Chengdu, China). To ensure the reliability of the results, all tests underwent laboratory internal quality control, and were within the control range.

2.3 Definition of Acute MP infection

An MP infection is defined by the presence of symptoms typical of ARTI, such as fever, cough, sore throat, and abnormal breath sounds. Additionally, a positive diagnosis requires either PCR testing indicating the presence of MP nucleic acids or serological testing showing the presence of MP specific IgM antibodies.

2.4 Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics, Version 27.0(IBM Corp.,Armonk,NY).Continuous variables are expressed as mean standard deviation （）,while categorical variables are presented as numbers (%).Group comparisons between variables were conducted using the Pearson’s chi-square test.Pearson correlation coefficient was employed to investigate the correlation between MP and various respiratory pathogens.P value <0.05was considered significant.

3.1 Study population

From January 1, 2018, to December 31, 2023, a total of 211,600 patients with acute respiratory tract infections (ARTI) were collected from Renmin Hospital of Wuhan University. Among them, 48, 542 cases did not meet the inclusion criteria, leaving a total of 163,058 cases included in the study, with an average age of 4.25 2.91 years. This included 93,575 males and 69,483 females. Among the included cases, 121,384 underwent MP specific IgM antibody testing on blood specimens, while 41,674 (including nasal swabs, nasopharyngeal swabs, sputum, and bronchoalveolar lavage fluid) underwent MP nucleic acid testing. A total of 49,936 cases tested positive for MP (45,602 positive for MP-IgM and 4,334 positive for MP-DNA), resulting in an overall positive rate of 30.62%. The specific process is detailed in Fig.1.

3.2 Seasonal and Annual Trends of MP Infections

From 2018 to 2023, the annual positive rates of MP among ARTI patients were 45.92%, 32.23%, 22.84%, 16.22%, 16.26%, and 42.93%, respectively. The differences in positive rates between each year were statistically significant (P<0.001). Throughout the entire study period, the highest positive rate was observed in autumn (35.13%), while the lowest was in spring (26.28%). The comparison of MP positive rates among seasons showed statistically significant differences (P<0.001). Between 2018 and 2019, spring and summer were the seasonal peaks, with positive rates of 50.24% and 49.20%, and 35.23% and 35.86%, respectively. In January 2020, the positive rate peaked at 27.39%, followed by a decline in February, reaching its lowest point in March (6.38%), gradually increasing in April, and maintaining a relatively stable level thereafter. In 2021 and 2022, the highest positive rates were observed in summer, with rates of 17.79% and 21.51%, respectively. However, in 2023, the highest number of MP cases sent for testing occurred in autumn and winter, consistent with the MP positive rates. Particularly, in late autumn and early winter, the monthly positive rates were 72.32% and 65.35%, respectively. The differences in seasonal positive rates each year were statistically significant (P<0.001). The specific distribution of monthly, seasonal, and annual MP infections during the study period is illustrated in Fig.2, and the detailed numerical values are provided in Table 1.

3.3 Age-related Characteristics and Temporal Trends of MP Infections

The 163,058 ARTI patients were divided into three age groups, with the positive rate for each age group: infants (21,436 cases, accounting for 25.32%), pre-school children (19,570 cases, accounting for 34.87%), and school-age children (8,930 cases, accounting for 40.09%). Among these, the school-age children group had the highest MP infection rate. The results for each age group are shown in Table 1. Further stratifying by detection time into three periods: 2018-2019, 2020-2022, and 2023, pre-school and school-age children were more common in all three years. The number of MP positive patients and the positive rates for each year group are shown in Fig.3. It's noteworthy that the positive rate increased with the age of the patients. Furthermore, we observed a linear relationship between the MP infection rates among patients aged 1 to 12 months throughout the months of the year, as depicted in Fig.4.

3.4 Gender Differences in MP Infection Positive Rates

Of the 49,936 confirmed infection cases, there were 23,726 females with an average positive rate of 34.15%, and 26,210 males with a positive rate of 28.01%. Despite a higher number of males being tested, the positive rate among females was significantly higher than that of males, with a statistically significant difference between the two groups (p < 0.001). Over the six years from 2018 to 2023, the positive rate among females was consistently higher than that of male patients, with rates of 50.71%, 36.68%, 25.66%, 19.17%, 18.46%, and 46.45%, respectively. The gender differences over the six-year period were statistically significant (p < 0.001). For specific numerical values, please refer to Table 1.

3.5 Prevalence and Patterns of Coinfections in MP Patients

In cases of MP infection, 7,126 cases were found to have at least one concurrent infection with another pathogen, with an overall positive rate of 14.27%. The yearly positive rates were 18.62%, 18.30%, 8.06%, 5.32%, 13.10%, and 12.98%, respectively, with statistically significant differences between the years (P<0.001). Among the 7,126 coinfected cases, 5,085 were found to have at least one concurrent viral infection (71.36%), while 2,041 were found to have at least one concurrent bacterial infection (28.64%). The study found that younger children were more likely to have coinfections with other pathogens, with infants (48.98%) > pre-school children (37.29%) > school-age children (13.74%), with statistically significant differences between age groups (P<0.001). The rate of coinfection was similar between genders (14.25% for males, 14.29% for females, P=0.914).

Among MP coinfections with viruses, the most commonly detected virus was influenza virus (IFV) (1,933 cases, accounting for 38.01%), followed by respiratory syncytial virus (RSV) (1,545 cases, accounting for 30.38%), human parainfluenza Virus (HPIV) (738 cases, accounting for 14.51%), human rhinovirus (HRV) (424 cases, accounting for 8.34%), human adenovirus (HAdV) (286 cases, accounting for 5.62%), human metapneumovirus (HMPV) (72 cases, accounting for 1.42%), human coronavirus (HCoV) (71 cases, accounting for 1.40%), and human bocavirus (HBoV) (16 cases, accounting for 0.31%). Genetic typing analysis of IFV showed that influenza B virus (FluB) predominated, accounting for 89.91% of all genetically analyzed cases, while influenza A virus (FluA) accounted for 10.09%. Among FluA coinfected patients, 66 cases of coinfection with influenza A subtype H3N2 (H3N2) were found, with no cases of coinfection with influenza A subtype H1N1 (H1N1) detected. Further age-specific analysis revealed that the top two viruses in all three age groups were IFV and RSV (42.10% and 34.53% for infants, 34.04% and 27.93% for pre-school children, 33.68% and 21.50% for school-age children, respectively), while the third-ranked virus in school-age children was HRV (16.84%). The pattern of virus coinfection was generally similar between infants and pre-school children (with HCoV > HMPV for preschool children), as shown in Fig.5.

Among MP coinfections with bacteria, the most commonly detected was Chlamydia pneumoniae (C.pneumoniae, CP) (1,286 cases, accounting for 63.01%), followed by Haemophilus influenzae (H.influenzae, Hi) (297 cases, accounting for 14.55%), Streptococcus pneumoniae (S.pneumoniae, Sp) (273 cases, accounting for 13.38%), Staphylococcus aureus (S.aureus, Sa) (81 cases, accounting for 3.97%), Acinetobacter baumannii (A.baumannii, Ab) (25 cases, accounting for 1.22%), Methicillin-Resistant Staphylococcus aureus (MRSA) (23 cases, accounting for 1.13%), Klebsiella pneumoniae (K.pneumoniae, Kp) (14 cases, accounting for 0.69%), Legionella pneumophila (L.pneumophila, Lp) (14 cases, accounting for 0.69%), Pseudomonas aeruginosa (P.aeruginosa, Pa) (12 cases, accounting for 0.59%), Coxiella burnetii (Coxiella burnetii, Cox) (7 cases, accounting for 0.34%), Escherichia coli (E.coli) (6 cases, accounting for 0.29%), Mycobacterium tuberculosis (M.tuberculosis, MTB) (2 cases, accounting for 0.10%), and Stenotrophomonas maltophilia (Stenotrophomonas maltophilia, Sm) (1 case, accounting for 0.05%). Further age-specific analysis showed that among the top three coinfection bacteria in all three age groups were C.pneumoniae, H.influenzae, and S.pneumoniae, albeit with slightly different orderings. In pre-school children, the order was C.pneumoniae > S.pneumoniae > H.influenzae. The ranking of coinfection patterns with other bacteria varied across different age groups, as shown in Fig.5.

Among the MP positive patients, 5,775 cases had single pathogen infections, while 641 cases exhibited coinfections involving at least two pathogens. The most common coinfection patterns with viruses were MP, HPIV and HAdV. The most common coinfection patterns with bacteria were MP, H. influenzae and S. pneumoniae. The most common coinfection patterns with bacterial and viruses were MP, RSV and C. pneumoniae. In addition, there were 64 cases with coinfections involving at least three pathogens. Among them, 7 cases involved MP mixed with 4 other pathogens, and 2 cases involved MP mixed with 5 other pathogens. The specific distribution and mutual relationships of coinfection pathogens can be found in Fig.6.

In this study, we provide a detailed description of the trend changes in MP infection among children under 14 years old in Wuhan from 2018 to 2023. We found that MP infection occurred continuously throughout the study period, with a monthly positive rate consistently above 10% (except in March 2020 and December 2022). Particularly notable was a significant outbreak observed from 2018 to 2019, similar to trends seen in other regions of China[18-22].During this outbreak, peaks of infection were mainly concentrated in the spring and summer, consistent with previous studies in the region[23].However, from 2020 to 2022, there was a notable decline in positive rates following the peak in January 2020 (27.39%), with both the total number of MP tests and positive rates significantly decreasing in February, reaching a low point in March (47 cases, 6.38%), representing declines of 82.64% and 78.71% compared to the same periods in 2018 and 2019, respectively.Positive rates gradually rebounded in April and remained stable and relatively low thereafter, with the highest rates occurring in the summer months of 2021-2022 (17.79% and 21.51%, respectively).We attribute this decline partly to reduced patient visits to healthcare facilities (particularly in 2020, when testing numbers were lowest) following the outbreak of the worldwide coronavirus disease (COVID-19), as well as the non-pharmaceutical interventions (NPIs) implemented in Wuhan at the time (including reducing gatherings, mask-wearing, hand hygiene, and disinfection), which likely effectively reduced the transmission of respiratory pathogens, including MP. However, despite the relaxation or cessation of NPI measures, MP infection rates continued to show a long-term decrease, while infections by other pathogens re-emerged during the same period, indicating an increase in community transmission[24, 25].By 2023, Wuhan experienced another localized MP outbreak, becoming a significant public health concern, consistent with multiple research findings[26, 27].We observed that in January 2023, positive rates remained low as in previous years, gradually increasing from February and peaking in the autumn and winter seasons. Particularly during late autumn and early winter, monthly positive rates reached 72.32% and 65.35%, respectively, consistent with findings from some European studies[22, 28, 29].Throughout the period from 2018 to 2023, there were fluctuations in the peak seasons of MP outbreaks in Wuhan, which we attribute to the influence of NPI measures adopted during the COVID-19 pandemic, altering people's behavior patterns and social activities, thereby affecting the transmission pattern of MP, either prolonging the epidemic period or due to changes in MP genotypes. MP typically experiences a major outbreak every 3-7 years, thus the resurgence of the epidemic in Wuhan in 2023 conforms to its cyclical epidemic pattern.

Most studies indicate that MP infection is more common in children aged 5 and above. Consistent with this, our study found that MP is more prevalent in pre-school and school-age children, in line with the findings of Meyer et al[30-34].We believe this could be due to the broader social contacts of children in this age group. In China, children typically start attending kindergarten around the age of 3 and begin primary school at 6-7 years old, spending most of their daytime in school,a densely populated places . This further supports the notion that MP infections often occur in places like schools and military bases through close contact and droplet transmission.Additionally, numerous studies suggest that after infecting host cells, MP can stimulate immune cells to produce a large number of cytokines and mediators, leading to clinical illness and lung injury[4, 35].Therefore, as children's immune function matures, their bodies can mount a more effective immune response against this pathogen. Our study results indicate that this trend is particularly pronounced in infants under 1 year old, with MP infection positive rates increasing with age. We speculate that breastfed infants may acquire protective antibodies from breast milk, which could be one reason for the lower infection rates in younger infants. Research has shown that antibodies induced in the mother's body during the perinatal period undergo specific post-translational modifications. When these antibodies are transferred to newborns through blood or breastfeeding, they can help young infants resist a wider range of pathogen infections[36].Overall, there is a general linear trend in the age distribution of MP infections in children.

In our study, the gender difference in MP infection is significant, with a notably higher positive rate among female patients compared to males, consistent with several previous domestic studies[20, 37-39]. We speculate that this difference may be due to genetic and hormonal factors. Sara et al. suggested that females have two X chromosomes, which contain multiple genes regulating immune function, such as interleukin-1 receptor-associated kinase 1 (IRAK1) and interleukin-2 receptor gamma chain. While one X chromosome is usually inactivated to prevent gene overexpression, this inactivation is only partial[40].They proposed that males may be more susceptible to bacterial and viral infections, while females may exhibit stronger immune responses. However, our study primarily detected MP IgM, which could potentially influence the detection results. Estradiol affects cellular immunity in a concentration-dependent manner. Susan and Sabra et al. suggested that low concentrations of estradiol can stimulate TH1-type responses, promoting the production of pro-inflammatory cytokines such as interleukin-1 and interferon-gamma[41, 42].

Respiratory tract infections caused by MP are difficult to distinguish from infections caused by other respiratory pathogens in terms of clinical symptoms and radiological findings. In pediatric ARTI, most MP infected patients are often co-detected with other viruses or bacteria, and this co-detection is associated with the severity of the disease[43, 44].In 14.27% of specimens collected from MP positive children, one or more other respiratory pathogens were detected. These pathogens may play a role in the pathogenesis of MP induced respiratory diseases, but their specific roles remain unclear. In our study, the most common viral coinfection was with IFV (mainly FluB), followed by RSV and HPIV. This differs from the findings of Maureen et al., who reported a lower coinfection rate of MP with influenza virus, RSV, and HPIV (<3.0%)[43]. For patients with combined viral infections, there may be no need to adjust their primary antibacterial treatment regimen. The most common bacterial coinfection was with C.pneumoniae, followed by H.influenzae and S.pneumoniae, similar to previous studies[45, 46].C. pneumoniae, like MP, is an atypical pathogen, and there is no significant difference in treatment regimens between the two. However, H. influenzae and S. pneumoniae are common strains, and MP is primarily treated with macrolide antibiotics. For children with combined infections of these two pathogens, additional antibiotics such as cephalosporins or fluoroquinolones may be needed for combination therapy. We also found that the incidence of coinfections is negatively correlated with age, with infants and young children being more commonly affected. This is consistent with the findings of Maureen et al[17, 43]. The interactions between MP and co-detected microorganisms and their potential impact on the severity of clinical symptoms in affected children require further research for deeper exploration.

Our study has several limitations. Firstly, being a retrospective study conducted in a single region and center, the representativeness of our sample may be biased. However, despite this limitation, the analysis of our large dataset over the past six years can still serve as guidance for preventing MP outbreaks in the region. Secondly, the sensitivity of PCR methods is higher than that of MP serological testing, especially for infants and young children, whose immune function may not be fully matured. As a result, some children may have false-negative results due to their serum antibody titers not being elevated. Directly using PCR methods for MP detection seems more reasonable. Unfortunately, due to potential cost-saving reasons, some patients in this study did not have both methods used in combination. This may have affected the positive rate of MP. Furthermore, we did not conduct genotyping or drug resistance analysis of MP, and thus could not determine whether the prevalent genotypes of MP had changed compared to previous outbreaks. Future studies could analyze data from more regions and incorporate clinical research to further explore the mechanisms and influencing factors of MP infections.

In summary, our study revealed the epidemiological trends, clinical characteristics, and coinfection relationships of MP among children in Wuhan. Two MP outbreaks occurred in Wuhan from 2018 to 2023, specifically in 2018-2019 and 2023. The NPI measures implemented during the COVID-19 pandemic also contributed to the delayed appearance of MP infections in Wuhan. However, MP re-emerged in 2023, becoming a significant contributor to the autumn and winter epidemics in the city. The high rate of coinfection between MP and other pathogens may lead to more severe clinical symptoms or the development of severe pneumonia, thereby increasing the burden on healthcare systems. These findings hold significant implications for informing clinical diagnosis and treatment, as well as shaping prevention and control strategies. Moreover, they offer valuable insights for future research endeavors related to this topic.

MP: Mycoplasma pneumoniae, M. pneumoniae

ARTI: Acute Respiratory Tract Infection

IFV: Influenza virus

Flu B: Influenza B virus

Flu A: Influenza A virus

H3N2: Influenza A subtype H3N2

H1N1: Influenza A subtype H1N1

RSV: Respiratory syncytial virus

HPIV: Human parainfluenza

HRV: Human rhinovirus

HAdV: Human adenovirus

HMPV: Human metapneumovirus

HCoV: Human coronavirus

HBoV: Human bocavirus

CP: Chlamydia pneumoniae, C.pneumoniae

Hi: Haemophilus influenzae, H.influenzae

Sp: Streptococcus pneumoniae, S.pneumoniae

Sa: Staphylococcus aureus, S.aureus

Ab: Acinetobacter baumannii, A.baumannnii

Kp: Klebsiella pneumoniae, K.pneumoniae

Lp: Legionella pneumophila, L.pneumophila

Pa: Pseudomonas aeruginosa, P.aeruginosa

Cox: Coxiella burnetii

E.coil: Escherichia coli

MTB: Mycobacterium tuberculosis, M.tuberculosis

Sm: Stenotrophomonas maltophilia

MRSA: Methicillin-Resistant Staphylococcus aureus

COVID-19: Coronavirus disease

NPI: Non-pharmaceutical interventions

Ethics approval and consent to participate

The procedures followed in this study were in accordance with principles of the Declaration of Helsinki (1964,amended most recently in 2008) of the World Medical Association.The protocol was approved by the Ethics Commission of Renmin Hospital of Wuhan University, and the requirement for patient informed consent was waived by the Ethics Commission of Renmin Hospital of Wuhan University due to the observational nature of the study.

Consent for publication

Not Applicable.

Availability of data and materials

Demographic and clinical data of patients which involved in this study were extracted from the Laboratory Information Systems of Renmin Hospital of Wuhan University. The datasets generated or analyzed during this study are not publicly available due to privacy or ethical restrictions but are available from the corresponding author on reasonable request.

Competing Interests

The authors declare that there was no conflict of interest.

Funding

This work was supported by The National Natural Science Foundation of China(82370008).

Author Contributions

JieYu Mao and ZhiLi Niu designed the study, conducted data organization and analysis, and drafted the initial manuscript. MengLing Liu and LiangYu Li participated in data organization and verification.HaiYue Zhang and RuiYun Li contributed to the study design and data interpretation. Pingan Zhang and XiaoJun Wu contributed to the study design, data interpretation, manuscript revisions, and final draft editing. All authors read and approved the final report.

Acknowledgements

This study was conducted at the Renmin Hospital of Wuhan University. We sincerely thank all the staff and participants for their important contributions.

Authors’ information

¹Department of Pulmonary and Critical Care Medicine, Renmin Hospital of Wuhan University Wuhan, Hubei, China.

²Department of Clinical Laboratory, Institute of Translational Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.

Clinical Trial Number

This study is a retrospective analysis using clinical data for statistical purposes. It does not involve patient privacy or human trials and is therefore exempt from the requirement for a clinical trial registration number.

Atkinson TP, Balish MF, Waites KB: Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS microbiology reviews 2008, 32(6):956-973.
Jacobs E, Ehrhardt I, Dumke R: New insights in the outbreak pattern of Mycoplasma pneumoniae. International journal of medical microbiology : IJMM 2015, 305(7):705-708.
Meyer Sauteur PM, Unger WWJ, van Rossum AMC, Berger C: The Art and Science of Diagnosing Mycoplasma pneumoniae Infection. The Pediatric infectious disease journal 2018, 37(11):1192-1195.
Waites KB, Talkington DF: Mycoplasma pneumoniae and its role as a human pathogen. Clinical microbiology reviews 2004, 17(4):697-728, table of contents.
Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP: Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clinical microbiology reviews 2017, 30(3):747-809.
Atkinson TP, Waites KB: Mycoplasma pneumoniae Infections in Childhood. The Pediatric infectious disease journal 2014, 33(1):92-94.
Kumar S: Mycoplasma pneumoniae: A significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. The Indian journal of medical research 2018, 147(1):23-31.
Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS et al: Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. International journal of antimicrobial agents 2008, 31(2):107-114.
Beeton ML, Zhang XS, Uldum SA, Bébéar C, Dumke R, Gullsby K et al: Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2020, 25(2).
Liu Y, Chen M, Zhao T, Wang H, Wang R, Cai B et al: Causative agent distribution and antibiotic therapy assessment among adult patients with community acquired pneumonia in Chinese urban population. BMC infectious diseases 2009, 9:31.
Xu M, Li Y, Shi Y, Liu H, Tong X, Ma L et al: Molecular epidemiology of Mycoplasma pneumoniae pneumonia in children, Wuhan, 2020-2022. BMC microbiology 2024, 24(1):23.
Ocak M, Öz FN, Çınar HG, Tanır G: Clinical and radiologic manifestations of Mycoplasma pneumoniae infection in children. The Turkish journal of pediatrics 2022, 64(6):1031-1040.
Yeh JJ, Wang YC, Hsu WH, Kao CH: Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study. The Journal of allergy and clinical immunology 2016, 137(4):1017-1023.e1016.
Sánchez-Vargas FM, Gómez-Duarte OG: Mycoplasma pneumoniae-an emerging extra-pulmonary pathogen. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008, 14(2):105-117.
He J, Liu M, Ye Z, Tan T, Liu X, You X et al: [Corrigendum] Insights into the pathogenesis of Mycoplasma pneumoniae (Review). Molecular medicine reports 2018, 17(3):4155.
Chiu CY, Chen CJ, Wong KS, Tsai MH, Chiu CH, Huang YC: Impact of bacterial and viral coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2015, 48(1):51-56.
Choo S, Lee YY, Lee E: Clinical significance of respiratory virus coinfection in children with Mycoplasma pneumoniae pneumonia. BMC pulmonary medicine 2022, 22(1):212.
Cai F, Shou X, Ye Q: Epidemiological Study on Mycoplasma pneumoniae and Chlamydia pneumoniae Infection of Hospitalized Children in a Single Center During the COVID-19 Pandemic. Frontiers in cellular and infection microbiology 2022, 12:843463.
Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K et al: Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2022, 27(19).
Wang X, Li M, Luo M, Luo Q, Kang L, Xie H et al: Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerging microbes & infections 2022, 11(1):1508-1517.
Tang M, Dong W, Yuan S, Chen J, Lin J, Wu J et al: Comparison of respiratory pathogens in children with community-acquired pneumonia before and during the COVID-19 pandemic. BMC pediatrics 2023, 23(1):535.
Wang F, Cheng Q, Duo H, Wang J, Yang J, Jing S et al: Childhood Mycoplasma pneumoniae: epidemiology and manifestation in Northeast and Inner Mongolia, China. Microbiology spectrum 2024, 12(5):e0009724.
Wu Z, Li Y, Gu J, Zheng H, Tong Y, Wu Q: Detection of viruses and atypical bacteria associated with acute respiratory infection of children in Hubei, China. Respirology (Carlton, Vic) 2014, 19(2):218-224.
Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML: Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? The Lancet Microbe 2022, 3(12):e897.
Meyer Sauteur PM, Beeton ML: Mycoplasma pneumoniae: gone forever? The Lancet Microbe 2023, 4(10):e763.
Larcher R, Boudet A, Roger C, Villa F, Loubet P: Mycoplasma pneumoniae is back! Is it the next pandemic? Anaesthesia, critical care & pain medicine 2024, 43(1):101338.
Meyer Sauteur PM, Beeton ML: Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions. The Lancet Microbe 2024, 5(2):e100-e101.
Wreghitt T: Mycoplasma pneumoniae: current outbreak. Epidemiology and infection 2024, 152:e47.
Yan C, Xue GH, Zhao HQ, Feng YL, Cui JH, Yuan J: Current status of Mycoplasma pneumoniae infection in China. World journal of pediatrics : WJP 2024, 20(1):1-4.
Chen K, Jia R, Li L, Yang C, Shi Y: The aetiology of community associated pneumonia in children in Nanjing, China and aetiological patterns associated with age and season. BMC public health 2015, 15:113.
Kawakami N, Namkoong H, Saito F, Ishizaki M, Yamazaki M, Mitamura K: Epidemiology of macrolide-resistant Mycoplasma pneumoniae by age distribution in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2021, 27(1):45-48.
Zhang L, Lai M, Ai T, Liao H, Huang Y, Zhang Y et al: Analysis of mycoplasma pneumoniae infection among children with respiratory tract infections in hospital in Chengdu from 2014 to 2020. Translational pediatrics 2021, 10(4):990-997.
Cheng Y, Cheng Y, Dai S, Hou D, Ge M, Zhang Y et al: The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic. Frontiers in cellular and infection microbiology 2022, 12:854505.
Ma J, Guo P, Mei S, Li M, Yu Z, Zhang Y et al: Influence of COVID-19 pandemic on the epidemiology of Mycoplasma pneumoniae infections among hospitalized children in Henan, China. Heliyon 2023, 9(11):e22213.
Yang J, Hooper WC, Phillips DJ, Talkington DF: Cytokines in Mycoplasma pneumoniae infections. Cytokine & growth factor reviews 2004, 15(2-3):157-168.
Erickson JJ, Archer-Hartmann S, Yarawsky AE, Miller JLC, Seveau S, Shao TY et al: Pregnancy enables antibody protection against intracellular infection. Nature 2022, 606(7915):769-775.
Lv YT, Sun XJ, Chen Y, Ruan T, Xu GP, Huang JA: Epidemic characteristics of Mycoplasma pneumoniae infection: a retrospective analysis of a single center in Suzhou from 2014 to 2020. Annals of translational medicine 2022, 10(20):1123.
Huang BX, Cai DF, Zhang JS, Lei M, Chen YS: Epidemiological characteristics of a single center for mycoplasma pneumoniae infection in a Children's Hospital in Shenzhen from 2011 to 2018 %J MolDiagnTher. 2023, 15(04):686-689.
Liaon SQ, Tan H, Zhang XM, Wan K, Lu XF, Zhu HC et al: Multicenter epidemiological characteristics of Mycoplasma pneumoniae infection in children in Hainan Province, 2012- 2020 %J China Tropical Medicine. 2023, 23(05):511-515+533.
Dias SP, Brouwer MC, van de Beek D: Sex and Gender Differences in Bacterial Infections. Infection and immunity 2022, 90(10):e0028322.
Kovats S: Estrogen receptors regulate innate immune cells and signaling pathways. Cellular immunology 2015, 294(2):63-69.
Klein SL, Flanagan KL: Sex differences in immune responses. Nature reviews Immunology 2016, 16(10):626-638.
Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM et al: Identification of Bacterial and Viral Codetections With Mycoplasma pneumoniae Using the TaqMan Array Card in Patients Hospitalized With Community-Acquired Pneumonia. Open forum infectious diseases 2016, 3(2):ofw071.
Jiang W, Wu M, Zhou J, Wang Y, Hao C, Ji W et al: Etiologic spectrum and occurrence of coinfections in children hospitalized with community-acquired pneumonia. BMC infectious diseases 2017, 17(1):787.
Ma L, Wang W, Le Grange JM, Wang X, Du S, Li C et al: Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. Infection and drug resistance 2020, 13:3045-3053.
Shin S, Koo S, Yang YJ, Lim HJ: Characteristics of the Mycoplasma pneumoniae Epidemic from 2019 to 2020 in Korea: Macrolide Resistance and Co-Infection Trends. Antibiotics (Basel, Switzerland) 2023, 12(11).

Table 1. Total number of cases and MP positive cases in different groups from 2018 to 2023

Group		Year n(%)
		2018		2019		2020		2021		2022		2023
Season
Spring		2 668(50.24%)		2 942(35.23%)		37(15.88%)		1 236(17.35)		1 005(12.63%)		2 243(23.44%)
Summer		2 534(49.20%)		2 836(35.86%)		284(22.42%)		1 259(17.79%)		2 180(21.51%)		3 326(35.71%)
Autumn		2 149(39.27%)		2 349(27.67%)		1 009(22.35%)		1 405(16.26)		891(16.47%)		9 925(55.30%)
Winter		2 655(45.34%)		2 093(30.08%)		854(24.06%)		822(13.11%)		574(11.25%)		2 660(48.74%)
c²		160.582		177.627		10.124		64.114		376.093		2878.993
P		<0.001		<0.001		0.018		<0.001		<0.001		<0.001
Age
0≤Age≤3		6 181(43.61)		5 305(27.51%)		1 074（18.76%）		2 380(14.09%)		1 904(13.01)		4 592(32.92%)
3<Age≤7		3 008(51.84%)		3 792(40.06%)		841（29.33%）		1 894(18.93%)		2 015(18.97%)		8 020(46.19%)
7<Age≤14		817(45.06%)		1 123(37.99%)		269(27.65%)		448(20.33%)		731(21.80%)		5 542(50.48%)
c²	112.808		507.613		135.360		138.030		246.363		900.917
P	<0.001		<0.001		<0.001		<0.001		<0.001		<0.001
Sex
Male	5 438(42.54%)		5 296(28.97%)		1 168(20.84%)		2 325(14.00%)		2 417(14.64%)		9 566(40.19%)
Female	4 568(50.71%)		4 924(36.68%)		1 016(25.66%)		2 397(19.17%)		2 233(18.46%)		8 588(46.45%)
c²	141.899		210.300		30.521		140.219		74.597		166.255
P	<0.001		<0.001		<0.001		<0.001		<0.001		<0.001

No competing interests reported.

Download PDF

Editorial decision: Revision requested
07 Aug, 2024
Editor invited by journal
01 Jul, 2024
Editor assigned by journal
28 Jun, 2024
Submission checks completed at journal
28 Jun, 2024
First submitted to journal
21 Jun, 2024

You are reading this latest preprint version

The Epidemiological Characteristics of Mycoplasma Pneumoniae Infection and Coinfection among Children in Central China from 2018 to 2023

Status:

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

1. Background

2. Materials and methods

3. Results

Discussion

Conclusions

Abbreviations

Declarations

References

Table

Additional Declarations

Status:

Version 1